Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received FDA approval for KHINDIVI, the first and only hydrocortisone oral solution available in the United States, marking a major milestone for ...

Eton Pharmaceuticals (NASDAQ:ETON) traded higher in the premarket on Thursday after the U.S. FDA approved its oral hydrocortisone solution Khindivi as a replacement therapy for children with ...

Eton Pharmaceuticals’ new drug application (NDA) for Khindivi, an oral solution of hydrocortisone, has received US Food and Drug Administration (FDA) approval as a replacement therapy for ...

Also Read: Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch Cortisol helps break down fats, proteins and carbohydrates in the body. Khindivi comes in a 1mg/ml ...

Investing.com -- Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) climbed 3.3% premarket following the announcement that the U.S. Food and Drug Administration (FDA) approved KHINDIVI ...

Investing.com -- Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) climbed 3.3% premarket following the announcement that the U.S. Food and Drug Administration (FDA) approved KHINDIVI™ (hydrocortisone) ...

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the US Food and Drug Administration (FDA) approval of ...

• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ...

DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...

(RTTNews) - Eton Pharmaceuticals Inc. (ETON) announced that the U.S. Food and Drug Administration has approved a New Drug Application (NDA) for KHINDIVI (hydrocortisone) Oral Solution. The drug is ...

Eton Pharmaceuticals has announced the FDA approval of KHINDIVI, the first and only hydrocortisone oral solution for pediatric patients aged five and older with adrenocortical insufficiency. The ...